| Cat.No. | Name | Information |
|---|---|---|
| M9173 | Cilengitide TFA | Cilengitide TFA is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M58555 | Volociximab | Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| M54150 | Cyclo(RADfK) | Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
| M54037 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. |
| M45151 | Lifitegrast sodium | Lifitegrast sodium is a potent integrin antagonist that blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen (LFA-1) and interrupts the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits the attachment of Jurkat T cells to ICAM-1 with an IC50 of 2.98 nM.May be useful in studies related to dry eye. |
| M45137 | Fuzapladib | Fuzapladib is a leukocyte adhesion molecule and an orally active inhibitor of leukocyte function-associated antigen type 1 (LFA-1) activation.Fuzapladib is also a phospholipase A2 (PLA2) inhibitor, which exerts anti-inflammatory activity by inhibiting the migration of leukocytes to sites of inflammation. |
| M40619 | Dentonin acetate | Dentonin acetate is an amino acid peptide derived from matrix extracellular phosphoglycoprotein (MEPE) and has the ability to promote the proliferation of dental pulp stem cells (DPSCs), which can be used in studies related to endodontic restoration and osteoarthritis (OA). |
| M30828 | BMS-688521 | BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model. |
| M29565 | Bexotegrast | Bexotegrast is a potent inhibitor of ανβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). |
| M25268 | Etaracizumab | Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer. |
| M25212 | Rovelizumab | Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke. |
| M24843 | Natalizumab | Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
| M24673 | Abciximab | Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors. |
| M21358 | Certepetide | Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating peptide whose RGD motif interacts with alphav-integrins and activates neurofibrillary protein 1 (NRP-1) to transform the solid tumor microenvironment into a temporary drug pipeline. Sequence Shortening: Ac-CRGDKGPDC-NH2 (Disulfide bridge: Cys1-Cys9). |
| M20872 | RGD peptide (GRGDNP) | RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. RGD peptide (GRGDNP) induces apoptosis presumably through direct activation of caspase-3. |
| M19984 | ILK-IN-3 | ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with anti-tumor activity. |
| M13756 | RGD Trifluoroacetate | RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins. |
| M13755 | iRGD peptide | iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
